Gerald H Yoon

University of Southern California, Los Angeles, CA, USA

Are you Gerald H Yoon?

Claim your profile

Publications (4)8.01 Total impact

  • Article: Tubeless percutaneous nephrolithotomy: a new standard in percutaneous renal surgery.
    Gerald H Yoon, Gary C Bellman
    Journal of endourology / Endourological Society 10/2008; 22(9):1865-7; discussion 1869. · 1.75 Impact Factor
  • Article: Rebuttal.
    Gerald H Yoon, Gary C Bellman
    Journal of endourology / Endourological Society 10/2008; 22(9):1871-2. · 1.75 Impact Factor
  • Article: Case report: subcapsular hepatic hematoma: retraction injury during laparoscopic adrenalectomy.
    Gerald H Yoon, Matthew D Dunn
    [show abstract] [hide abstract]
    ABSTRACT: We present a case of subcapsular hepatic hematoma resulting from retraction of the liver during laparoscopic adrenalectomy. We discuss the management and prevention of this rare and important complication.
    Journal of Endourology 03/2006; 20(2):127-9. · 1.85 Impact Factor
  • Article: Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
    Gerald H Yoon, John P Stein, Donald G Skinner
    [show abstract] [hide abstract]
    ABSTRACT: Nonseminomatous germ cell tumors of the testicle are highly treatable and curable. The evolution of cancer control for this disease has demonstrated an effective integration of medical and surgical approaches over the last 30 years. Current emphasis in the therapy of nonseminomatous germ cell tumors focuses on minimizing treatment-related morbidity while maintaining consistently high cure rates. Retroperitoneal lymph node dissection in experienced hands is a critical component of the treatment armamentarium in this disease. Retroperitoneal lymph node dissection is an accurate staging tool that provides important information in determining the need for chemotherapy. When performed properly, retroperitoneal lymph node dissection eliminates the retroperitoneum as a site for relapse, which in turn provides emotional and psychological relief to the patient and simplifies the follow-up protocol. Retroperitoneal lymph node dissection alone can also provide high cure rates in patients with clinical low-stage disease and high-risk factors such as lymphovascular invasion or predominance of embryonal histology in the primary tumor. Teratoma is known to be chemoresistant and, when present in the primary tumor of low-stage patients, may be best treated with primary retroperitoneal lymph node dissection. Primary chemotherapy in the treatment of low-stage nonseminomatous germ cell tumors deserves continual investigation as long-term toxicities become more apparent. Observation is an option for the highly motivated patient, but requires a rigorous follow-up schedule to avoid relapse. Laparoscopic retroperitoneal lymph node dissection is a viable staging tool, however, oncologic control of the retroperitoneum has not been reliably determined.
    Expert Review of Anti-infective Therapy 03/2005; 5(1):75-85. · 2.65 Impact Factor